Casdin Capital as of Dec. 31, 2020
Portfolio Holdings for Casdin Capital
Casdin Capital holds 51 positions in its portfolio as reported in the December 2020 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Invitae (NVTAQ) | 15.2 | $514M | 12M | 41.81 | |
Biolife Solutions Com New (BLFS) | 8.8 | $297M | 7.4M | 39.89 | |
Fate Therapeutics (FATE) | 8.2 | $277M | 3.1M | 90.93 | |
EXACT Sciences Corporation (EXAS) | 5.8 | $197M | 1.5M | 132.49 | |
Blueprint Medicines (BPMC) | 5.1 | $174M | 1.6M | 112.15 | |
Relay Therapeutics (RLAY) | 4.7 | $158M | 3.8M | 41.56 | |
Twist Bioscience Corp (TWST) | 4.2 | $141M | 1.0M | 141.29 | |
Pacific Biosciences of California (PACB) | 3.8 | $130M | 5.0M | 25.94 | |
Denali Therapeutics (DNLI) | 3.3 | $110M | 1.3M | 83.76 | |
Agios Pharmaceuticals (AGIO) | 3.0 | $103M | 2.4M | 43.33 | |
Alnylam Pharmaceuticals (ALNY) | 3.0 | $101M | 780k | 129.97 | |
Codexis (CDXS) | 2.8 | $95M | 4.3M | 21.83 | |
Sarepta Therapeutics (SRPT) | 2.7 | $90M | 530k | 170.49 | |
Caredx (CDNA) | 2.6 | $87M | 1.2M | 72.45 | |
Revolution Medicines (RVMD) | 1.9 | $65M | 1.6M | 39.59 | |
Constellation Pharmceticls I | 1.5 | $51M | 1.8M | 28.80 | |
Generation Bio (GBIO) | 1.4 | $46M | 1.6M | 28.35 | |
Dermtech Ord ord (DMTKQ) | 1.3 | $44M | 1.4M | 32.44 | |
Burning Rock Biotech Sponsored Ads | 1.3 | $44M | 1.9M | 23.10 | |
Adaptive Biotechnologies Cor (ADPT) | 1.2 | $42M | 713k | 59.13 | |
Crispr Therapeutics Namen Akt (CRSP) | 1.2 | $41M | 266k | 153.11 | |
Bluebird Bio (BLUE) | 1.2 | $40M | 915k | 43.27 | |
Adverum Biotechnologies | 1.2 | $40M | 3.7M | 10.84 | |
Beigene Sponsored Adr | 1.1 | $39M | 150k | 258.39 | |
Beam Therapeutics (BEAM) | 1.1 | $38M | 460k | 81.64 | |
Global Blood Therapeutics In | 1.1 | $37M | 860k | 43.31 | |
4d Molecular Therapeutics In (FDMT) | 1.0 | $32M | 781k | 41.45 | |
Magenta Therapeutics | 0.8 | $26M | 3.3M | 7.84 | |
Zai Lab Adr (ZLAB) | 0.8 | $26M | 190k | 135.34 | |
Iovance Biotherapeutics (IOVA) | 0.8 | $26M | 550k | 46.40 | |
Alector (ALEC) | 0.7 | $25M | 1.7M | 15.13 | |
Allogene Therapeutics (ALLO) | 0.7 | $24M | 945k | 25.24 | |
908 Devices (MASS) | 0.7 | $23M | 407k | 56.95 | |
Taysha Gene Therapies Com Shs (TSHA) | 0.6 | $22M | 820k | 26.54 | |
Oric Pharmaceuticals (ORIC) | 0.6 | $20M | 602k | 33.85 | |
Berkeley Lts | 0.5 | $18M | 200k | 89.41 | |
Kronos Bio (KRON) | 0.5 | $17M | 583k | 29.87 | |
Sangamo Biosciences (SGMO) | 0.5 | $17M | 1.1M | 15.60 | |
Fulcrum Therapeutics (FULC) | 0.4 | $15M | 1.2M | 11.71 | |
Amyris Call Option | 0.4 | $12M | 2.0M | 6.17 | |
Syndax Pharmaceuticals (SNDX) | 0.3 | $10M | 450k | 22.24 | |
Black Diamond Therapeutics (BDTX) | 0.3 | $9.3M | 289k | 32.05 | |
Turning Point Therapeutics I | 0.3 | $9.1M | 75k | 121.85 | |
Seer Com Cl A (SEER) | 0.2 | $8.4M | 150k | 56.14 | |
Abcellera Biologics (ABCL) | 0.2 | $8.0M | 200k | 40.24 | |
Dyne Therapeutics (DYN) | 0.2 | $7.8M | 370k | 21.00 | |
Stoke Therapeutics (STOK) | 0.2 | $7.4M | 120k | 61.93 | |
Foghorn Therapeutics (FHTX) | 0.1 | $4.4M | 216k | 20.27 | |
Bristol-myers Squibb Right 99/99/9999 | 0.1 | $4.3M | 6.3M | 0.69 | |
Codiak Biosciences | 0.1 | $2.5M | 77k | 32.30 | |
C4 Therapeutics Com Stk (CCCC) | 0.0 | $1.3M | 40k | 33.12 |